News

Severe or inflammatory acne can result in prominent scarring in affected patients, which highlights the importance of grading acne in diagnosis of the skin condition.

The investigators found pharmacotherapy for AUD was associated with a lower incidence of hepatic decompensation in patients with cirrhosis.

Efanescotocog alfa is the first factor VIII therapy to be granted Breakthrough Therapy designation by the FDA.

Childhood BMI, SBP, and total cholesterol level among those risk factors associated with adult cardiovascular events.

Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.

Investigators observed that patients with quantifiable levels of brodalumab following 12 weeks of therapy experienced significantly higher PASI reductions that those without.

Massimo Radin, MD, PhD, explains how tailoring oral therapy in rheumatoid arthritis, via the TuTOR App, can improve medication adherence.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

The NDA submission is based on results from the Phase 3 DERBY and OAKS studies and the Phase 2 FILLY study.

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

“The role of terminally differentiated T effector memory re-expressing Temra in RA pathogenesis and disease activity is still unclear," investigators stated.

Eliseo Pascual, MD, PhD, discusses sex and gender regarding the diagnosis, treatment, and management of rheumatic disease.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.

Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.

AXS-05 also showed superiority to placebo in safety.

A greater prevalence of hidradenitis suppurativa, psoriasis, folliculitis, and hirsutism in pediatric patients with obesity compared to the general pediatric population.

SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.

Most adverse events reported were mild or moderate and found in a similar percentage of patients regardless of treatment cohort.

Nicola Luigi Bragazzi, MD, PhD, explains the importance of sex-based medicine in psoriatic arthritis and shares his advice for future studies.

New data suggests there is no connection between ustekinumab and the risk of malignancies.

While the long-term efficacy and safety of the biologic has been investigated in, few studies have been based on real life experience.

There are several companies preparing new treatments for recurrent C difficile infections.

Dupilumab is the first and only biologic to show positive Phase 3 results in patients with prurigo nodularis.

There are several potential treatments on the horizon for C difficile infections.

The meta-analysis included more than 11,000 patients with between 8 and 9 years of mean follow-up periods.

Catch up on Rheumatology Network's top articles of May 2022.

Screening and early-life interventions for these patients may prevent cardiometabolic outcomes, according to investigators.

Primary care provider Dr. Gerald Smetana shares key information and resources to give PCPs all they need know about prescribing outpatient therapies for COVID-19.

The public perception of marijuana has shifted significantly, and Dr. Timothy Fong addresses how to keep up with progressive research and what risk factors still need to be better understood.